Medchart Targets the Records Backlog in Canada's $2.521B Tobacco Fund

Marble's Medchart platform launched a dedicated medical records service on Sept. 2, 2026 for claimants under Canada's Pan-Canadian Claimants' Compensation Plan, the $2.521 billion fund set aside for eligible tobacco-disease claimants, collecting diagnosis records with claimant consent.

Every mass compensation fund eventually runs into the same wall: the money is agreed long before the paperwork is. Marble, the Toronto company behind the medical records platform Medchart, is betting that wall is where the value sits.

Medchart said it has launched a dedicated medical records service for claimants under the Pan-Canadian Claimants' (PCC) Compensation Plan, the $2.521 billion fund set aside for eligible claimants. The service collects the diagnosis records a claim depends on, with the claimant's consent, and is pitched as a replacement for the fax-and-follow-up-call routine that still governs how Canadian health records move between clinics, hospitals and administrators.

Why proof of diagnosis is the gating item

Compensation plans of this kind are structured around eligibility categories rather than individual litigation. A claimant does not argue a case; they demonstrate that they fit a defined category. In practice that means producing documentation from a treating institution showing a qualifying diagnosis, its date, and enough clinical context to place the claimant inside the plan's criteria.

That single requirement is where mass claims processes tend to stall. The records exist, but they sit in different systems at different institutions, each with its own release process, its own consent form, and its own queue. A claimant who moved provinces, changed family doctors, or was diagnosed at a hospital that has since merged its records system can spend months assembling what an administrator will accept.

The volume problem compounds it. A fund sized at $2.521 billion implies a claimant population large enough that records departments receive requests in waves rather than one at a time — and those departments are staffed for routine clinical demand, not for a settlement surge.

What Medchart is actually selling

Medchart describes itself as Canada's medical record request and release platform, and the new offering applies that infrastructure to a single, defined use case. The core mechanic is consent-based retrieval: the claimant authorizes the request, and the platform handles the routing to the holding institutions and the return of the documents, rather than the claimant chasing each provider individually.

The distinction matters legally as well as operationally. Health records in Canada are governed provincially, and release without valid, documented patient consent is not merely bad practice — it is a privacy breach. A platform that captures and carries that consent through the chain is selling compliance as much as speed.

The company announced the launch from Toronto, according to the release carried by Financial Post.

The economics of a records bottleneck

Settlement funds are finite pools. When claims are slow to substantiate, three things happen at once, and none of them are neutral for claimants.

• Administrative cost rises. Every incomplete file that has to be returned, queried and resubmitted consumes administrator time, and administration is typically paid out of the same architecture that funds claims.
• Payment timing stretches. Claimants in these plans are, by definition, people with serious disease diagnoses. Delay is not an abstraction for them; for some it is the difference between receiving compensation and having an estate receive it.
• Eligible people drop out. The most under-discussed failure mode of any claims process is attrition. People who cannot assemble the documents simply stop trying, and the fund under-distributes to precisely the population it was created for.

That last point is what a retrieval service is really addressing. The barrier is rarely eligibility. It is the friction between being eligible and being able to prove it on a form.

A health-tech niche built on administrative failure

Medchart's product sits in a category that has grown steadily on both sides of the border: software that monetizes the gap between how digital health data is stored and how slowly it is actually released. Insurers, personal injury firms, disability adjudicators and life underwriters all buy the same underlying service — get the record, get it legally, get it in a usable format.

Mass settlements are an unusually clean market for that pitch. The document requirement is standardized, the claimant population is identifiable, and there is a defined administrative counterparty on the receiving end. Compared with one-off litigation support, a compensation plan gives a records vendor something close to a repeatable workflow.

The open questions are the ones the launch announcement does not answer: how the service is priced, who bears that cost, whether the plan's administration has any formal relationship with the platform, and what share of the claimant population it can realistically reach. Those details will determine whether this is meaningful infrastructure for the fund or a commercial product operating alongside it.

The market backdrop for the announcement

Marble is not a listed company, so there is no share price to read the news through. The launch landed against a soft North American tape. In the most recent session before the announcement, closing Sept. 1, 2026, the S&P 500 tracker SPY finished at $761.78, down 0.69% from a prior close of $767.05, within a day range of $759.48 to $764.67. The Nasdaq 100 proxy QQQ closed at $707.64, off 1.27% from $716.76, and the Dow tracker DIA ended at $527.75, down 0.72% from $531.57. All three closed lower, with the tech-weighted index taking the largest hit.

None of that bears directly on a private Toronto health-tech launch, but it frames the environment for the sector: capital for administrative-workflow software is being priced more carefully than it was, and products with a defined, immediate customer base tend to fare better than platform stories in that setting.

What to watch from here

The measurable outcomes for a service like this are not product features. They are claims metrics: the share of submitted files that are complete on first pass, the elapsed time from consent to record delivery, and ultimately how much of the $2.521 billion reaches claimants versus how much is consumed getting there.

Watch, too, for whether Canadian records-holding institutions standardize their release processes in response to the volume. Mass claims events have historically been the forcing function for administrative reform in health data — the surge exposes exactly which parts of the system still run on paper. A platform can route around a fax machine. It cannot, on its own, retire one.

Key facts

• Fund size: $2.521 billion Pan-Canadian Claimants' Compensation Plan
• Launch: Medchart dedicated medical records service, announced from Toronto
• Mechanism: Diagnosis records collected with the claimant's consent
• Market backdrop: SPY closed $761.78 (-0.69%), QQQ $707.64 (-1.27%), DIA $527.75 (-0.72%) — as of 20:00 GMT, Sept. 1, 2026

Frequently asked questions

What is the Pan-Canadian Claimants' Compensation Plan?

It is the compensation structure holding $2.521 billion set aside for eligible claimants in Canada's tobacco settlement. Rather than individual lawsuits, claimants demonstrate that they meet defined eligibility criteria, which generally requires documentation of a qualifying medical diagnosis from the institutions that treated them.

What did Medchart launch?

Medchart, the platform operated by Toronto-based Marble, launched a dedicated medical records service for claimants under the Pan-Canadian Claimants' Compensation Plan. The service collects the diagnosis records a claim depends on, with the claimant's consent, in place of the fax requests and follow-up phone calls that typically govern record release.

Why are medical records a bottleneck in settlement claims?

Records sit across multiple institutions, each with separate release processes, consent forms and queues. Claimants who changed doctors, moved provinces or were treated at facilities that later merged systems can spend months assembling documents. Incomplete files get returned and resubmitted, stretching payment timelines and causing some eligible people to abandon their claims entirely.

Is Marble a publicly traded company?

No. Marble, the company behind the Medchart platform, is private, so there is no exchange-listed share price attached to this announcement. Investors cannot take a direct position in the launch; the relevant read-across is to the broader market for health-records and claims-administration software.

Why does claimant consent matter in this process?

Health records in Canada are governed by provincial privacy legislation, and releasing them without valid, documented patient authorization is a breach rather than a procedural lapse. A retrieval platform that captures consent and carries it through to each holding institution is selling regulatory compliance alongside speed of delivery.

How did North American markets close before the announcement?

In the session ending 20:00 GMT on Sept. 1, 2026, the S&P 500 tracker SPY closed at $761.78, down 0.69%. The Nasdaq 100 proxy QQQ finished at $707.64, down 1.27%, and the Dow tracker DIA closed at $527.75, down 0.72%. All three benchmarks ended the day lower.

Sources

• Marble Launches Dedicated Medical Records Service to Remove Biggest Bottleneck in Canada’s $2.521 Billion Tobacco Settlement — Financial Post

Photo: Luis F Rodríguez Jiménez · Pexels Licence — source